# Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT04155840** · PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 1 (actual)

## Conditions studied

- Lymphoid Leukemia
- Non-Hodgkin's Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Copanlisib
- **BIOLOGICAL:** Rituximab
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT04155840
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-31
- **Primary completion:** 2021-03-16
- **Final completion:** 2021-03-16
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Terminated due to low accrual
- **Last updated:** 2022-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04155840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04155840, "Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04155840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*